Acro Biomedical Co., Ltd. vs Moderna, Inc.
Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.
In short
- Moderna, Inc. is the larger company by market value: $90.1 B against $240 M for Acro Biomedical Co., Ltd., 376 times as much (market caps of Dec 25, 2022 for Acro Biomedical Co., Ltd. and Oct 30, 2026 for Moderna, Inc.). Acro Biomedical Co., Ltd.'s value is the last on file, from Dec 25, 2022: no market-data feed is connected for its exchange yet.
- Both made a net loss: $0 M for Acro Biomedical Co., Ltd. and $2.8 B for Moderna, Inc.
Market value, the same start = 100
From Jan 2020: how each one's value moved, whatever its size.
Revenue by fiscal year
US$ billions, as reported in each year's annual results.
Side by side
| Measure | Acro Biomedical Co., Ltd. ACBM | Moderna, Inc. MRNA · #274 in the world |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Founded | 2014 | 2010 |
| Size | ||
| Market cap | $240 M* | $90.1 B |
| Revenue | — | $1.9 B |
| Net income | $-0 M▲ best | $-2.8 B |
| Employees | — | 4,700 |
| Valuation | ||
| Price to sales | — | 35.7× |
| Price to book | — | 10.4× |
| Free cash flow yield | — | -2.3% |
| Profitability | ||
| Gross margin | — | 55.4% |
| Operating margin | — | -158.1% |
| Net margin | — | -145.2% |
| Return on equity | — | -28.9% |
| Growth | ||
| Revenue growth | — | -39.9% |
| Revenue growth, 3 years a year | — | -53.4% |
| Financial strength | ||
| Debt to equity | — | 0.1× |
| Cash | ||
| Free cash flow margin | — | -106.2% |
| Shareholder returns | ||
| Shareholder yield | — | 0.0% |
| Strength scores | ||
| Piotroski F-score | — | 3 of 9 |
| Altman Z-score zone | — | safe |
| Data as of | Market cap Dec 2022; ratios FY2025 | Market cap Oct 2026; ratios FY2025 |
Questions and answers#
Which is bigger, Acro Biomedical Co., Ltd. or Moderna, Inc.?
Moderna, Inc. is the larger company by market value: $90.1 B against $240 M for Acro Biomedical Co., Ltd., 376 times as much (market caps of Dec 25, 2022 for Acro Biomedical Co., Ltd. and Oct 30, 2026 for Moderna, Inc.). Acro Biomedical Co., Ltd.'s value is the last on file, from Dec 25, 2022: no market-data feed is connected for its exchange yet.
Which makes more money, Acro Biomedical Co., Ltd. or Moderna, Inc.?
Both made a net loss: $0 M for Acro Biomedical Co., Ltd. and $2.8 B for Moderna, Inc.